TORONTO, Oct. 26, 2016 /PRNewswire/ - Concordia
International Corp. ("Concordia" or "the Company") (NASDAQ:
CXRX) (TSX: CXR), an international specialty pharmaceutical company
focused on generic and legacy pharmaceutical products and orphan
drugs, today announced it intends to release its third quarter 2016
financial results before market open on Monday, November 7, 2016.
The Company will subsequently hold a conference call that same
day, Monday, November 7, 2016, at
8:30 a.m. ET, hosted by senior
management. A question-and-answer session will follow the corporate
update.
CONFERENCE CALL
DETAILS
|
|
DATE:
|
Monday, November 7,
2016
|
|
|
TIME:
|
8:30 a.m.
ET
|
|
|
DIAL-IN
NUMBER:
|
(647) 427-7450 or
(888) 231-8191
|
|
|
TAPED
REPLAY:
|
(416) 849-0833 or
(855) 859-2056
|
|
|
REFERENCE
NUMBER:
|
4801308
|
This call is being webcast and can be accessed by going to:
http://event.on24.com/r.htm?e=1294639&s=1&k=395B0457ED01AA9F6D4C2668EA9D31B9
An archived replay of the webcast will be available by clicking
the link above.
About Concordia
Concordia is a diverse, international specialty pharmaceutical
company focused on generic and legacy pharmaceutical products and
orphan drugs. The Company has an international footprint with sales
in more than 100 countries, and has a diversified portfolio of more
than 200 established, off-patent molecules that make up more than
1,300 SKUs. Concordia also markets orphan drugs through its Orphan
Drugs Division, consisting of Photofrin® for the treatment of
certain rare forms of cancer, which is currently undergoing testing
for potential new indications.
Concordia operates out of facilities in Oakville, Ontario and, through its
subsidiaries, operates out of facilities in Bridgetown, Barbados; London, England and Mumbai, India.
Notice regarding forward-looking statements:
This news release includes forward-looking statements within the
meaning of the United States Private Securities Litigation Reform
Act of 1995 and forward-looking information within the meaning of
Canadian securities laws, regarding Concordia and its business,
which may include, but are not limited to, statements with respect
to the release date of Concordia's financial results. The
forward-looking events and circumstances discussed in this news
release may not occur by certain dates or at all and could differ
materially as a result of known and unknown risk factors and
uncertainties affecting Concordia, including risks associated with
Concordia's securities, increased indebtedness and leverage,
Concordia's growth, risks associated with the use of Concordia's
products, the inability to generate cash flows, revenues and/or
stable margins, the inability to repay debt and/or satisfy future
obligations, risks associated with Concordia's outstanding debt,
risks associated with the geographic markets in which Concordia
operates and/or distributes its products, risks associated with
distribution agreements, the pharmaceutical industry and the
regulation thereof, regulatory investigations, the failure to
comply with applicable laws, economic factors, market conditions,
risks associated with growth and competition, the failure to obtain
regulatory approvals, the equity and debt markets generally,
general economic and stock market conditions, risks associated with
fluctuations in exchange rates (including, without limitation,
fluctuations in currencies), political risks (including changes to
political conditions), risks associated with the United Kingdom's exit from the European Union
(including, without limitation, risks associated with regulatory
changes in the pharmaceutical industry, changes in cross-border
tariff and cost structures and the loss of access to the European
Union global trade markets), risks related to patent infringement
actions, the loss of intellectual property rights, risks and
uncertainties detailed from time to time in Concordia's filings
with the Securities and Exchange Commission and the Canadian
Securities Administrators, and many other factors beyond the
control of Concordia. Although Concordia has attempted to identify
important factors that could cause actual actions, events or
results to differ materially from those described in
forward-looking statements and information, there may be other
factors that cause actions, events or results to differ from those
anticipated, estimated or intended. No forward-looking statement or
information can be guaranteed. Except as required by applicable
securities laws, forward-looking statements and information speak
only as of the date on which they are made and Concordia undertakes
no obligation to publicly update or revise any forward-looking
statement or information, whether as a result of new information,
future events, or otherwise.
SOURCE Concordia International Corp.